76results about How to "Reduce reabsorption" patented technology

The present invention relates to dialysis solutions for peritoneal dialysis, containing hydroxyethyl starch as the osmotically-active substance, electrolytes and, optionally, conventional additives, where the hydroxyethyl starch has a molecular weight Mw in the range from 10,000 to 150,000, a substitution MS in the range from 0.10 to 0.40, a substitution DS in the range from 0.09 to 0.35 and a substitution ratio C2 / C6>=8. With this peritoneal dialysis solution it is possible, with an outstanding ultrafiltration, to maintain a longer dwell time, for example the dialysis solution can be utilized for a period of 12 hours in the CAPD without replacement. In addition, the inventive dialysis solution is also particularly advantageous for patients with residual kidney function. The resorption of the osmotically active substance is clearly diminished and even after a dwell time of 12 hours it amounts to a maximum of 60-70%.

The slimming diet fiber biscuit is produced with flour and diet fiber as main material and supplementary material including salt, seasoning, etc. The diet fiber will expand after absorbing water and this makes the eater produce satiety to reduce the ingestion; and it will reduce the time for food to stay in intestinal tract to consume fat inside body and result in slimming effect. In addition, ingesting diet fiber can reduce the re-absorption amount and alter food digesting speed and digestion secretion amount to prevent gall stone, duodenal ulcer, peptic colonitis and other diseases.

A gallium nitride (GaN) based light emitting device, wherein the device comprises a first surface and a second surface, and the first surface and second surface are separated by a thickness of less than 100 micrometers, and preferably less than 20 micrometers. The first surface may be roughened or textured. A silver or silver alloy may be deposited on the second surface. The second surface of the device may be bonded to a permanent substrate.

A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.

The invention relates to an optical-fiber laser, in particular to a 1.7mum all-optical-fiber thulium-doped quartz optical-fiber laser based on a two-directional pumping structure. The 1.7mum all-optical-fiber thulium-doped quartz optical-fiber laser comprises a pumping source, an isolator and a laser resonance cavity, wherein the laser resonance cavity comprises an optical-fiber Bragg grating A, an optical-fiber Bragg grating B, an optical-fiber Bragg grating C, a wavelength division multiplexer and a thulium-doped quartz optical fiber. The 1.7mum all-optical-fiber thulium-doped quartz optical-fiber laser has the advantages that high-reflectivity optical-fiber grating at the wavelength position of the pumping source to reflect forward pumping light which cannot be completely absorbed back into the laser resonance cavity so as to form a simple and ingenious two-directional pumping structure. Due to the structure, the problem of low pumping-light absorbing efficiency caused by low doping concentration and short length of thulium-doped gain optical fiber can be effectively solved.

The invention belongs to the technical field of drug delivery device products, and particularly relates to a targeted drug delivery device for an anti-tumor magnetic nanometer particle drug. The device comprises a liquid conveying container, a drug liquid conveying device and a control unit, wherein a magnetic field generation device and a biological electric sensor are arranged on the body surface of a tumor area, the magnetic field generator is connected with a magnetic field control device, the drug liquid conveying device is connected with a flow rate controller, and the control unit is respectively connected with the biological electric sensor, the magnetic field control device and the flow rate controller. The targeted drug delivery device can reduce the flowing of the magnetic nanometer particle anti-tumor drug, and the drug can be well centralized into the tumor area, so the concentration of the drug in the tumor area is higher, and the medical effect is good; meanwhile, the strength of a magnetic field and the flow rate of drug liquid can be controlled according to the feedback of the biological electric signals of the tissues of the tumor area, the therapy safety of the magnetic nanometer particle drug is improved, the restoration of the body of a tumor patient is facilitated, and the unnecessary injury to other organs of the body by the drug is also reduced.

The present invention relates to light-converting materials which comprise semiconductor nanoparticles and an unactivated crystalline material, where the semiconductor nanoparticles are located on the surface of the unactivated crystalline material. The present invention furthermore relates to the use of the light-converting material in a light source. The present invention furthermore relates to a light-converting mixture, to a light source, to a lighting unit which contains the light-converting material according to the invention, and to a process for the production of the light source.

A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.

The present invention is light aggregate pre-treating process and apparatus. The light aggregate is first pressurized and humidified in a sealed pressure container as the light aggregate pre-treating apparatus in the pressure of 5-8 MPa for 30-120 min to reach water absorbing rate of 60-80 %; and then shell forming treated through mixing with cement for 90-180 min, with the cement adding amount being 50-100 kg for 1 cu m of aggregate without free water, to form watertight shell in the surface of the aggregate. The present invention has high aggregate pre-treating speed, high efficiency, and capacity keeping free water amount and maintaining high pumpability of the concrete.

Composition comprising one or more energy donors and one or more energy acceptors, wherein energy is transferred from the energy donor to the energy acceptor and wherein: the energy acceptor is a colloidal nanocrystal having a lower band gap energy than the energy donor; the energy donor and the energy acceptor are separated by a distance of 40 nm or less; wherein the average peak absorption energy of the acceptor is at least 20 meV greater than the average peak emission energy of the energy donor; and wherein the ratio of the number of energy donors to the number of energy acceptors is from about 2:1 to about 1000:1.

A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.

The invention discloses an Sr and Mg doped amorphous apatite material and crystalline apatite material, belonging to the field of biomedical materials. The different concentrations of Sr and Mg doped amorphous apatite material is rapidly prepared by using Ca(NO3)2, Mg(NO3)2, Sr(NO3)2, (NH4)2HPO4 and ammonia-water as raw materials and then is transformed to the different concentrations of Sr and Mg doped nano calcium-deficient hydroxyapatite or nano tricalcium phosphate material through heat treatment. Compared with traditional hydroxyapatite crystalline materials, the amorphous material has higher solubility. The amorphous apatite material and the crystalline apatite material have the beneficial effects that after Sr and Mg doping, Sr can achieve the effects of promoting new bone formation, reducing reabsorption of bone, adjusting calcium metabolism and reducing the activity of osteoclast, and Mg can achieve the effects of affecting early growth of bone substances and regulating growth and remodelling of the bone substances; therefore the synthesized amorphous apatite and the crystallized product thereof have important roles in the fields of bone repair and bone transplantation.

The invention provides a composition for protecting the liver. The composition is prepared from the following components in parts by weight: 1-7 parts of a kudzuvine root extract, 0.5-5 parts of a radix salviae miltiorrhizae extract, 0.1-4 parts of an emblic leafflower fruit extract, 0.5-5 parts of lucid ganoderma spore powder and 0.5-6 parts of a turmeric extract. The composition provided by the invention adopts plant varieties with homology of medicines and foods, thereby having small side effects to a human body and avoiding the metabolic burden on the liver during long-term administration. Furthermore, after the several substances are compounded, the interaction is realized, and chemical liver injuries are better inhibited, so that the effect of protecting the liver is realized. The invention further provides a preparation method of the composition, a traditional Chinese medicine preparation prepared from the composition and excipients, and application of the composition in preparation of health care products for protecting the liver against the chemical injuries.

The invention relates to a functional degreased sheep milk product and process for preparation, wherein the product is prepared from defatted sheep milk or its restored milk, soybean dietary fiber, fructooligosaccharide, xylitol, stabilizer, flavoring agent and water through steps of mixing homogeneously, dissolving, hydrating, homogenizing, sterilizing and packaging.

The invention belongs to the field of medicines or health products, and particularly relates to a novel use of sesquiterpenoid in reducing uric acid. The sesquiterpenoid has a structure represented byformula (I): wherein X, R1-R11 are as defined in the description of the invention. Through an animal model of hyperuricemia, the sesquiterpenoid of the invention is found to promote uric acid excretion in vivo, has an obvious effect of reducing uric acid, and can be used as a potential medicine for reducing uric acid or treating gout.

The present invention provides a method for controlling an optical property of a wavelength conversion sheet. The method is a method for controlling an optical property of a wavelength conversion sheet that contains a transparent resin and a phosphor and achieves wavelength conversion by absorbing light in a specific wavelength range other than a target wavelength range and emitting light in a target wavelength range, wherein the phosphor contains a phosphor having a perylene skeleton, and a stokes shift of the wavelength conversion sheet is controlled by adjusting a concentration of the phosphor having a perylene skeleton to the transparent resin in a range of 0.5% to 3.5% by weight.

A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.

The invention provides a luminescent material comprising a component selected from the group comprising (Y1-xLux)9LiSi6O26:Ln or / and AE5(PO4)3F:Ln,A, wherein Ln is a trivalent rare earth metal, AE is a divalent alkaline earth metal, and A is a monovalent alkaline metal, x > 0.0 and < 1.0. The luminescent material has an emission peak in the UV-C range when being excited by light in the UV spectrum range. The invention further provides a light emitting device comprising the said luminescent material and a method of using said light emitting device for disinfection or purification of air, water or surfaces.

The invention relates to a red-blue-light glass ceramic light conversion component. The component comprises a first blue fluorescent glass ceramic body and a second red fluorescent glass ceramic body,wherein the first blue fluorescent glass ceramic body is formed in the way that blue fluorescent powder and phosphate glass powder are mutually mixed and subjected to melting and solidification; theblue fluorescent powder is selected from one or more of a fluorescent material with a molecular formula of BaMgAl<10>O<17>:Eu<2+>, a fluorescent material with a molecular formula of CaF<2>:Eu<2+> anda fluorescent material with a molecular formula of CaAl<2>O<4>:Eu<2+>; the second red fluorescent ceramic body is formed in the way that red fluorescent powder and phosphate glass powder are mutuallymixed and subjected to melting and solidification; the red fluorescent powder is selected from one or more of a fluorescent material with a molecular formula of CaAlSiN<3>:Eu<2+>, a fluorescent material with a molecular formula of Y<3>Al<5>O<12>:Mn<4+> and a fluorescent material with a molecular formula of 3.5MgO.0.5MgF<2>.GeO<2>:Mn<4+>; and the first blue fluorescent glass ceramic body and the second red fluorescent glass ceramic body are mutually spliced to form the red-blue-light glass ceramic light conversion component. The red-blue-light glass ceramic light conversion component can adaptto a near-ultraviolet LED chip to emit blue light with wavelength ranging from 400nm to 500nm and red light with wavelength ranging from 580nm to 780nm; and the peak width at half height of a spectrumof the blue light is up to 50nm, so that the requirement of plant growth is better met, light emitting efficiency is higher, and light quality is easier to adjust.

A luminescence conversion of LED, which uses a blue emitting chip and two illuminating substances, whereby one emits a red and the other a yellow to green. Both illuminating substances are separated upstream from the chip.

A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.

The invention belongs to the field of drugs or health care products, and particularly relates to new application of sesquiterpenoids to uric acid lowering. The sesquiterpenoids include the structure shown in a formula (I) (please see the specification for the formula (I)), wherein R1, R2, R3 and R4 are shown as definitions of a specification of the invention. Through a hyperuricemia animal model,it is found that the sesquiterpenoids promote uric acid excretion in vivo, has the significant uric acid lowering effect, and can serve as a potential drug for lowering uric acid or treating gout.

The invention provides a high-power LED packaging structure. The high-power LED packaging structure comprises a reflective cup and an integrated packaging substrate, wherein the reflective cup is a groove formed on the surface of the integrated packaging substrate; a lens is arranged at the upper end of the reflective cup; a bonding layer, an LED chip, a dispensing layer and a phosphor powder layer are sequentially arranged in a cavity formed by the lens and the reflective cup; and an electrode for connecting the LED chip and a drive circuit is arranged on the integrated packaging substrate. The LED packaging structure provided by the invention adopts integrated package to avoid heat dissipation bottleneck in traditional LEDs; and the layered dispensing layer enables the LED chip to be far away from the phosphor powder layer, so that light re-absorption of the LED chip in the traditional packaging structure is reduced, and the light emitting rate and the light distribution performance are improved. The LED packaging structure provided by the invention not only has a simple structure but also omits a bracket, an aluminum baseplate and a heat sink part in traditional package, thereby reducing the process steps, lowering the cost and facilitating industrial production.

The invention relates to a food composition assisting in reducing blood sugar and blood fat. The food composition is prepared from 10-300 parts of inulin, 5-200 parts of alpha-linolenic acid microcapsules, 50-200 parts of stachyose and 20-110 parts of euglena powder. The food composition is definite in efficacy, clear in mechanism, reasonable in proportion, significant in synergistic effect, higher in pertinence and safety and suitable for a wider range of people.

Pharmaceutical formulations comprising raloxifene or its salts, esters, polymorphs, isomers, hydrates, solvates, or derivatives thereof having defined particle sizes. Also described are processes for preparing formulations and methods of using such formulations.

Peptidic dual GLP-1 / Glucagon Receptor Agonists derived from Exendin-4 The present invention relates to dual GLP-1 / glucagon receptor agonists or optionally trigonal GLP-1 / glucagon / GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

The invention provides a Chinese traditional medicine compound injection and preparation method, wherein the compound comprises Notoginsen triterpenes, ammonium glycyrrhizinato, sodium chloride, glucose, mannitol, lactose, sorbitol, dextran as the clinically accept, osmoregulation agent, freeze drying excipient and water for injection. The components can be prepared into injection, high volume injection and freeze dried injection.

The invention relates to the field of fiber laser, in particular to a mid-infrared 4mu m fiber laser amplifier based on a Dy-doped chalcogenide glass fiber, which mainly structurally comprises a pumping source, a focusing lens, a Dy-doped chalcogenide glass fiber, a dichroic mirror, a reflector and a signal source. According to the 4-micron waveband intermediate infrared optical fiber amplifier based on the chalcogenide gain optical fiber, stable, high-gain, high-signal-to-noise-ratio and wavelength-continuously-adjustable 4-micron waveband amplified signal laser output is achieved, and the problem that the output power of a current 4-micron waveband laser light source is low is solved.

The invention discloses a composite fluorescent film, a preparation method thereof, and an application of the film in laser display. The film comprises an orange red fluorescent film coating and a green fluorescent film coating which are arranged on a substrate. The preparation method of the film comprises the following steps: uniformly coating a high-thermal-conductivity ceramic matrix with an orange red phosphor-glass powder mixed slurry, heat-curing the mixed slurry to form the orange red fluorescent film coating, uniformly coating the orange red fluorescent film coating with a green phosphor-glass powder mixed slurry, and heat-curing the mixed slurry to form the green fluorescent film coating in order to obtain the composite fluorescent film. The composite fluorescent film can emit white light after the multicolor fluorescent film is excited by a blue light LD, and is applied to the field of laser display. The composite fluorescent film prepared by the method has excellent luminescence properties, can form wide-color-gamut color development on the basis of simplifying the structure of the white-light LD, and has great scientific research significance and commercial values.

The invention relates to a prebiotic composition containing inulin, and a preparation method and use of the composition. The prebiotic composition containing inulin prepared in the invention comprisesinulin, a traditional Chinese medicine extract and malt; the inulin is a mixture of GFn (n=2-60); and the traditional Chinese medicine extract is one or two of balsam pear extract or polygonatum extract, and the particle size is 40-60 mesh. The preparation method of the prebiotic composition containing inulin includes: (1) crushing and sieving the traditional Chinese medicine extract; (2) crushing and sieving the malt; (3) mixing the traditional Chinese medicine extract and the malt in equal increment to obtain a mixture A; (4) mixing the inulin and the mixture A evenly; and (5) conducting packing and sealing. According to the present invention, the prepared prebiotic composition containing inulin has a good synergistic effect of lowering blood sugar and blood lipid, can not only reduce the hyperglycemia of diabetic patients, but also reduce the complication hyperlipemia. At the same time, the probiotic composition has high safety, and does not cause allergic reaction due to the introduction of exogenous probiotics, and the preparation method is simple and easy.